We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

TCF Theracryf Plc

-0.05 (-5.41%)
21 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Theracryf Plc TCF London Ordinary Share
  Price Change Price Change % Share Price Last Trade
-0.05 -5.41% 0.875 13:20:56
Open Price Low Price High Price Close Price Previous Close
0.925 0.875 0.925 0.875 0.925
more quote information »
Industry Sector

Theracryf TCF Dividends History

No dividends issued between 23 Jun 2014 and 23 Jun 2024

Top Dividend Posts

Top Posts
Posted at 04/6/2024 20:03 by terrydevlin1
Good luck Mark and CT. Whilst the Stalicla deal is still live I can’t see how this can go down much lower. But that deal looks to be on the rocks IMO. The fact TCF no longer mentioned up to $5.5m expected this year in the full results and Stalicla also removed from their website that this would go into phase 2 in 2024, it doesn’t look good. If the deal collapses this share price will be 0.1p and it’s game over. I question where is the money going to come from to bankroll this company? TCF needs between £3m and £4m a year which is enormous sums of money.
I’ve been doing alright recently on the virtual dogs at the bookies, I’d rather stick a grand on a virtual dog than this dog of a share.
Posted at 28/5/2024 17:15 by xxproinvestorxx
Tcf FY26E is March 31st 2026.
Posted at 28/5/2024 17:14 by xxproinvestorxx
I didn't hear that in the presentation, however, when writing going concerns they can only report on what happened in the reported period, not after, except for the part that mentions post period. Also look at the research notes issued today, they also say cash into 2026. Say they expect TCF to "close FY26E with a closing cash balance of just under 0.3m"
Posted at 26/5/2024 12:34 by terrydevlin1
I don’t know how anyone can think the results will be positive at all. Terrible 12 months here. No income, Juvenesense deal collapsed, Stalicla dispute, no new contracts signed, a share placing, money running out, next to no news on SFX-01 progressing. I think TCF may have a decent drug in SFX-01 buy they can’t afford to do any trials and can’t get anyone to trial it for them. Even if TCF get the $5.5m they hoped by the end of the year, where is the next income coming from? Stalicla payments clearly can’t be relied on. The end goal is already written here, another share placement which happens every 2 years is inevitable at some point. The shares will be diluted so much that there is no possibility of shareholders making any money here. There is no hope of TCF ever succeeding now. Don’t waste your time or money here.
Posted at 10/5/2024 07:12 by terrydevlin1
I agree with your comment Clock Tower. It is incredibly disappointing to have no new deals signed up for SFX-01 since the Stalicla deal. There seems so little news now about SFX-01 in the past 10 months.
The sad reality is that TCF cannot afford to do their own trials so they cannot do much to prove the drug is effective and it seems like they cannot get anyone to trial it for them.
The Stalicla deal is so huge to TCF that they have no option but to wait for Stalicla to decide what they will do and when they will do it. It is TCF’s only potential income stream and money is running out. It is over a quarter of a year since the dispute was issued and no news at all. It doesn’t feel like there will be any news any time soon either.

I feel for all investors who invested as a result of the Stalicla deal announcement in 2022. At that time with £10m in the bank, Juvenesense having a deal with SFX-01 and milestone payments of up to $160m with Stalicla it seemed like this share had great potential. I wish I never had stumbled on that RNS.
Posted at 13/7/2017 20:40 by rjmahan
Glad I sold out of this - lucky escape. I had hoped they would be able to sell down property and repay debt but it obviously hasnt happened like that.

Still not entirely convinced its a complete no hoper, debt / NAV was 57% !, telecom assets are high quality - though there is a lot of junk in there too.

There was a eur 20m (from memory) payment due in 2017 - part of reason I sold out. Surely can be renegotiated again?

Dont entirely trust laxley not to try to pick up TCF on the cheap... Dont think we are anywhere near the bottom yet though....
Posted at 31/12/2014 17:51 by rjmahan
Sales + Low liquidity. If you read report TCF wont be able to pay out for several years (I estimate 4) unless sold. However after 4 years I recon this can have a 10% yield.
Posted at 08/1/2013 16:04 by praipus
Also surprised we havent seen an "ex-divi" dip. Edit ok guess we wont see one due to the nature of the return.
Posted at 31/10/2012 09:19 by skyship
Been a nice 4month rally for TCF holders. I considered buying sub-40p, but put off by that large Spazio holding (30% of the portfolio).

Too late to chase; and the same concern remains.

What really interests me here is what they plan to do with the TEIF holding. Any views?
Posted at 10/9/2012 20:58 by praipus
I've misread the situation here.

Slow liquidations are good, very good. They help you by:

1) Stopping you (or us PI's) over trading and or the market movements wrong footing you
2) they have just as much chance (probability) of yeilding a high return as you have of picking another stock and making a gain.
3) "loss aversion" puts PI's off making the stock cheap as they exit prior to delisting but the odds of an eventual profit dont necessarily change.
4) reduce dealing and management charges.

Still rather have Laxey or Weiss dominate the share register than RBS, Northern Rock or another seemingly big safe "but risk blind" name.

TCF is odd (with hind sight) only because of its narrow real estate bias.

Your Recent History

Delayed Upgrade Clock